Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries. The company sells its products directly to hospitals or office-based labs. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:CSII
CUSIP14161910
Phone651-259-1600
Debt
Debt-to-Equity Ratio0.17
Current Ratio4.46
Quick Ratio3.99
Price-To-Earnings
Trailing P/E Ratio754.10
Forward P/E Ratio1,878.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$217.04 million
Price / Sales5.76
Cash Flow$0.1559 per share
Price / Cash241.00
Book Value$3.62 per share
Price / Book10.38
Profitability
EPS (Most Recent Fiscal Year)$0.05
Net Income$1.71 million
Net Margins0.79%
Return on Equity1.39%
Return on Assets0.89%
Miscellaneous
Employees579
Outstanding Shares33,260,000
Market Cap$1.25 billion
Cardiovascular Systems (NASDAQ:CSII) Frequently Asked Questions
What is Cardiovascular Systems' stock symbol?
Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."
How were Cardiovascular Systems' earnings last quarter?
Cardiovascular Systems Inc (NASDAQ:CSII) issued its quarterly earnings data on Monday, July, 30th. The medical device company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.05. The medical device company earned $59.15 million during the quarter, compared to analysts' expectations of $58.43 million. Cardiovascular Systems had a net margin of 0.79% and a return on equity of 1.39%. View Cardiovascular Systems' Earnings History.
When is Cardiovascular Systems' next earnings date?
What price target have analysts set for CSII?
7 brokers have issued 12 month price targets for Cardiovascular Systems' stock. Their forecasts range from $23.00 to $50.00. On average, they expect Cardiovascular Systems' stock price to reach $34.3333 in the next year. This suggests that the stock has a possible downside of 8.6%. View Analyst Price Targets for Cardiovascular Systems.
What is the consensus analysts' recommendation for Cardiovascular Systems?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cardiovascular Systems.
What are Wall Street analysts saying about Cardiovascular Systems stock?
Here are some recent quotes from research analysts about Cardiovascular Systems stock:
- 1. According to Zacks Investment Research, "Cardiovascular Systems exited fourth-quarter fiscal 2018 on a solid note primarily on year-over-year improvement in both Coronary device and peripheral device segments. The company is putting efforts in product innovation through R&D investments. Further, management seems to be upbeat about the recently-signed exclusive international distribution agreement with OrbusNeich to sell its coronary and peripheral orbital atherectomy systems outside the United States and Japan. The market is also looking forward to the recently-launched coronary device in Japan, reflecting the company’s focus on international expansion. Over the past six months, Cardiovascular Systems has outperformed its industry. On the flip side, the company faces cut-throat competition in the niche space. Further, its failure to successfully enter international markets and manage business on a global scale, might negatively affect the company’s financial results." (8/3/2018)
- 2. Needham & Company LLC analysts commented, "CSII’s F3Q18 revenue met consensus while EPS beat consensus. Management’s F4Q18 revenue guidance bracketed consensus while EPS guidance was above consensus. The F4Q18 revenue guidance requires a substantial acceleration from F3Q18 but we note that CSII faces a significantly easier revenue growth comp in F4Q18 than in F3Q18 (9.2% vs. 17.3%). Looking into FY19, CSII should continue to benefit from the Japanese launch, new support products, building rep productivity, and a further easing of comps so we think it can see its revenue growth accelerate further. However, it remains to be seen if CSII can sustain double- digit revenue growth and considering its 3.0x 2018E EV/sales multiple, we maintain our Hold rating." (5/3/2018)
Are investors shorting Cardiovascular Systems?
Cardiovascular Systems saw a decrease in short interest during the month of July. As of July 13th, there was short interest totalling 579,228 shares, a decrease of 36.1% from the June 29th total of 907,153 shares. Based on an average trading volume of 209,638 shares, the days-to-cover ratio is presently 2.8 days. Approximately 1.8% of the shares of the stock are short sold. View Cardiovascular Systems' Current Options Chain.
Who are some of Cardiovascular Systems' key competitors?
Some companies that are related to Cardiovascular Systems include Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR), NuVasive (NUVA), Merit Medical Systems (MMSI), Irhythm Technologies (IRTC), Nevro (NVRO), Tandem Diabetes Care (TNDM), Glaukos (GKOS), Mazor Robotics (MZOR), Luminex (LMNX), Cryolife (CRY), Atrion (ATRI), AtriCure (ATRC) and Tactile Systems Technology (TCMD).
Who are Cardiovascular Systems' key executives?
Cardiovascular Systems' management team includes the folowing people:
- Mr. Scott Raymond Ward MS, B.Sc., Chairman, Chief Exec. Officer and Pres (Age 58)
- Mr. Laurence L. Betterley, VP of Admin. (Age 64)
- Ms. Laura J. Gillund, Chief Talent Officer (Age 57)
- Mr. Jeffrey S. Points, Chief Financial Officer
- Ms. Rhonda J. Robb, Chief Operating Officer
Has Cardiovascular Systems been receiving favorable news coverage?
Media coverage about CSII stock has been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cardiovascular Systems earned a media and rumor sentiment score of 0.09 on Accern's scale. They also assigned media coverage about the medical device company an impact score of 46.37 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for Cardiovascular Systems.
Who are Cardiovascular Systems' major shareholders?
Cardiovascular Systems' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.46%), Partner Fund Management L.P. (3.70%), Cortina Asset Management LLC (2.45%), Frontier Capital Management Co. LLC (2.33%), Renaissance Technologies LLC (2.26%) and FMR LLC (1.55%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Camber Capital Management Llc, Edward M Brown, Jeffrey S Points, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Paul A Koehn and Scott R Ward. View Institutional Ownership Trends for Cardiovascular Systems.
Which institutional investors are selling Cardiovascular Systems stock?
CSII stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., First Manhattan Co., Renaissance Technologies LLC, Cortina Asset Management LLC, Dynamic Technology Lab Private Ltd, Frontier Capital Management Co. LLC, Gabelli Funds LLC and BlueMountain Capital Management LLC. Company insiders that have sold Cardiovascular Systems company stock in the last year include Alexander Rosenstein, Edward M Brown, Jeffrey S Points, Laura Gillund and Scott R Ward. View Insider Buying and Selling for Cardiovascular Systems.
Which institutional investors are buying Cardiovascular Systems stock?
CSII stock was purchased by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., FMR LLC, Millennium Management LLC, BlackRock Inc., Granahan Investment Management Inc. MA, DAFNA Capital Management LLC, California Public Employees Retirement System and First Light Asset Management LLC. View Insider Buying and Selling for Cardiovascular Systems.
How do I buy shares of Cardiovascular Systems?
Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cardiovascular Systems' stock price today?
One share of CSII stock can currently be purchased for approximately $37.56.
How big of a company is Cardiovascular Systems?
Cardiovascular Systems has a market capitalization of $1.25 billion and generates $217.04 million in revenue each year. The medical device company earns $1.71 million in net income (profit) each year or $0.05 on an earnings per share basis. Cardiovascular Systems employs 579 workers across the globe.
How can I contact Cardiovascular Systems?
Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected]
MarketBeat Community Rating for Cardiovascular Systems (NASDAQ CSII)
MarketBeat's community ratings are surveys of what our community members think about Cardiovascular Systems and other stocks. Vote "Outperform" if you believe CSII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSII will underperform the S&P 500 over the long term. You may vote once every thirty days.
